levidopa, carbidopa, and the original question
Just to clarify: Levodopa is L-dihydroxy-phenylalanine or ortho-hydroxy-tyrosine (essentially, tyrosine with a hydroxy group adjacent to the one already present on the phenyl ring) and it is a direct precursor to dopamine. levodopa is analogous to 5-HTP in that only a decarboxylation step is necessary to produce either dopamine or serotonin, respectively. Unfortunately, levodopa is almost entirely decarboxylated in the periphery, which means that taking levodopa alone (except in massive doses) will only minimally elevate DA levels in the CNS. For levodopa to be clinically efficacious, it must be administered with carbidopa, a peripheral decarboxylase inhibitor (peripheral because it does not cross the blood brain barrier).
As to the original question, it is unlikely that anyone will ever isolate a substance that acts on the mesolimbic dopamine pathway alone. Nature doesn't wast things too often, so if she can use one receptor subtype in two pathways, she probably will, so it's unlikely that you will find a receptor subtype exclusively inhabiting the DA ventral tegmental (VTA) ganglion.
Keep in mind that to activate the pathway from its point of initiation (ie, in the midbrain ganglion), one should not necessarily administer a classic DA agonist. In fact, amphetamine inhibits the firing of DA neurons in vitro (see reference below) presumably by evoking Ca-independent release of DA which binds to autoreceptors in the VTA. Many other transmitter receptors reside on the VTA cells bodies, which is why opiates, nicotine, alcohol, benzos, etc., all excite the mesolimbic pathway. When you take amphetamine, you are not "lighting up" the pathway in this manner: you are causing DA release from terminals at the end of the pathway...if this is confusing, let me know.
Reference: "The Biochemical Basis of Neuropharmacology" by Cooper, Bloom, and Roth.